Evidence map›Paper›PMID 27288508›Full record

ArticleBiology open2016

Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions.

Preeti Bais, Kirk Beebe, Kathryn H Morelli, Meagan E Currie, Sara N Norberg, Alexei V Evsikov, Kathy E Miers, Kevin L Seburn, Velina Guergueltcheva, Ivo Kremensky and 3 more

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Preeti BaisThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Kirk BeebeMetabolon Inc., Durham, 27713 NC, USA.
Kathryn H MorelliThe Jackson Laboratory, Bar Harbor, 04609 ME, USA Graduate School of Biomedical Science and Engineering, University of Maine, Orono, 04469 ME, USA.
Meagan E CurrieThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Sara N NorbergThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Alexei V EvsikovThe Jackson Laboratory, Bar Harbor, 04609 ME, USA Department of Molecular Medicine, USF Health, University of South Florida, Tampa, 33620 FL, USA.
Kathy E MiersThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Kevin L SeburnThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Velina GuergueltchevaDepartment of Neurology, Medical University-Sofia, 1431 Sofia, Bulgaria.
Ivo KremenskyNational Genetics Laboratory, Department of Obstetrics and Gynecology, University Hospital of Obstetrics and Gynecology, Medical University-Sofia, 1431 Sofia, Bulgaria.
Albena JordanovaMolecular Neurogenomics Group, VIB Department of Molecular Genetics, University of Antwerp, 2610 Antwerpen, Belgium Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 1431 Sofia, Bulgaria.
Carol J BultThe Jackson Laboratory, Bar Harbor, 04609 ME, USA.
Robert W BurgessThe Jackson Laboratory, Bar Harbor, 04609 ME, USA Graduate School of Biomedical Science and Engineering, University of Maine, Orono, 04469 ME, USA robert.burgess@jax.org.ORCID http://orcid.org/0000-0002-9229-3407
Jackson Laboratory · USMedical University of Sofia · BGMetabolon (United States) · USUniversity of Antwerp · BEUniversity of South Florida · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Genetics of the Neuromuscular Junction: Mechanisms and Disease ModelsR01NS054154 · NINDS · JACKSON LABORATORY · PI BURGESS, ROBERT W. · 2006 to 2019
$6.0M
Summer Research Experience in Neurobiology at The Jackson LaboratoryR25NS078795 · NINDS · JACKSON LABORATORY · PI Robert W. Burgess, Laura J Muller · 2012 to 2026
$708k
Metabolite Profiling of a Novel Mitochondrial Kinase in Neuromuscular DiseaseR21NS082666 · NINDS · JACKSON LABORATORY · PI BULT, CAROL J, BURGESS, ROBERT W. · 2013 to 2014
$479k
NCI NIH HHS P30 CA034196NINDS NIH HHS R01 NS054154NINDS NIH HHS R21 NS082666NINDS NIH HHS R25 NS078795
6 · The paper itself

Abstract

Charcot-Marie-Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot-Marie-Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite 'fingerprint' we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.

Indexed as

Mass SpectrometryMetabolomicsPeripheral neuropathySciatic nerveSpinal cordtRNA synthetase

Identifiers

PMID27288508
PMCPMC4958279
OpenAlexW2418941559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.